O

Otsuka Pharmaceutical

Global pharma maker of Abilify

Rare Disease Account Manager

Full-TimeUpdated on 10/23/2026Deadline 11/9/26
$132k - $205.4k+ Incentive opportunity
Mid
Bachelor's, Master's, MBA
Remote in USA+5 moreMore locations: Salem, OR, USA | Portland, OR, USA | Vancouver, WA, USA | Bend, OR, USA | Eugene, OR, USA
RemoteTerritory includes Oregon and Southern Washington; remote-sales scope is listed for the United States.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree is required.
  • Three or more years of sales experience in rare disease, immunology, renal, oncology, and/or hospital account management is strongly preferred.
  • A proven track record of consistently meeting or exceeding financial and/or other quantitative targets, as well as qualitative goals, in a fast-paced dynamic sales environment is required.
  • The candidate must demonstrate intellectual curiosity, business acumen, perseverance, relationship mastery, collaboration, and passion for patients.
  • The candidate must be able to interpret, analyze, and leverage data to identify trends, gain insights, drive pull-through, and lead live customer engagements in the local business environment.
  • The candidate must demonstrate strategic thinking to create a customer/account engagement plan using a dynamic and collaborative approach to maximize the business.
  • The candidate must maintain awareness of trends in their area of expertise and use knowledge and insights to positively impact the business.
  • The candidate must collaborate respectfully with internal and external stakeholders and incorporate diverse views into decision-making within a complex and competitive healthcare environment, including payers, health systems, and matrix partners.
  • The candidate must apply expert knowledge of the marketplace, competitors, industry, and matrix functional activities and plans to anticipate and manage business opportunities and challenges in an ambiguous environment.
  • The candidate must demonstrate commitment to ethical business practices, understand regulatory standards, and execute business activities in compliance with company policies and guidance.
  • The candidate must facilitate clinical dialogue that motivates customers to act on behalf of their patients, engage the entire account to understand obstacles, and provide appropriate solutions to meet customer needs.
  • The candidate must develop and position Otsuka as a leader with key nephrology stakeholders and other specialty customers and targeted large-group and community-practice accounts.
  • The candidate must use competitive data and business reports, including sales data and promotional budget information, to track progress and uncover opportunities.
  • The candidate must understand territory and business conditions that affect sales results and use them to establish near-term priorities for the territory business plan.
  • The candidate must respond compliantly to competitive threats and opportunities.
  • The candidate must educate office staff on payer guidelines and reimbursement procedures to increase pull-through.
  • The candidate must effectively use promotional materials.
  • The candidate must maintain awareness of internal support team resources and use them appropriately.
  • The candidate must apply market and industry knowledge to overcome objections and influence prescribing habits during total-office calls.
  • The candidate must identify territory professional groups to network with and ensure access to potential key opinion leaders.
  • The candidate must build strong relationships with key office and practice personnel, focus conversations on patient health, take responsibility for follow-through, and provide accurate information in response to account needs.
  • The candidate must deliver effective and balanced office calls and sales presentations using approved marketing materials and technical references, such as studies and package inserts, and demonstrate competent knowledge of the product and competition.
Responsibilities
  • Work with the Area Business Lead, Rare Disease, to develop a territory-specific business/account plan with strategies and tactics to increase disease-state awareness, implement diagnostic approaches, identify and pursue business opportunities, and meet rare-disease sales goals.
  • Collaborate with cross-functional colleagues, including other Rare Disease Account Managers, brand marketing, market access, medical affairs, and thought leader liaisons, to meet business objectives.
  • Develop in-depth knowledge of current and future competition and execute sales strategies to compete effectively and achieve patient-acquisition and revenue goals.
  • Build and maintain proficiency in relevant disease states, patient and clinic experience, market landscape, and product knowledge.
  • Use available tools, technology, and resources to analyze information and identify market opportunities and trends.
  • Navigate the healthcare landscape, including academic institutions, integrated delivery networks, community practices, and local patient advocacy groups, to identify opportunities.
  • Execute the rare disease selling model.
  • Sponsor and display at relevant congresses and society meetings.
  • Manage longer selling cycles and complex patient journeys across the product portfolio.
  • Serve as the primary point of contact for healthcare-provider customers and accounts, addressing complex on-label information based on approved content in a competitive landscape.
  • Coordinate with cross-functional colleagues in medical, market access, patient support, and thought leader liaison functions within appropriate guardrails.
Desired Qualifications
  • An MBA or other related graduate degree is preferred.

About the company

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT's August 2026 two-year data supports a supplemental FDA approval filing.
  • Transcend acquisition closed June 15, 2026, adding a differentiated neuropsychiatry pipeline.
  • Paradise renal denervation gained Japan insurance coverage March 1, 2026, accelerating sales.

What critics are saying

  • Abilify patents keep expiring through 2027, pressuring a legacy revenue engine.
  • Otsuka v Sun Pharma in Australia threatens ABILIFY MAINTENA patent-extension protection.
  • Transcend's PTSD asset, TSND-201, reaches Phase 3 completion only in late 2027.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs pharmaceuticals, devices, and diagnostics across renal, psychiatric, and cardiovascular care.
  • SIMTRIYO, approved July 23, 2026, is the first approved NDSRI for ADHD.
  • VOYXACT delivered 24-month eGFR stabilization, strengthening Otsuka's IgA nephropathy leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Tuition Reimbursement
  • Student Loan Assistance
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Otsuka US
Sep 20th, 2026
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments | Otsuka US

Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions.

Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.